#drug-pricing

#drug-pricing

Medicare recipients will save $1.5 billion on medication costs starting in 2026 through negotiated drug prices.

Medicare's new drug price negotiations will provide significant savings for older adults, impacting 10 commonly used and expensive medications.

The upcoming election could dramatically influence healthcare policy affecting millions of Americans.

Two-thirds of Americans believe healthcare deserves more focus in the election discussions.

The IRA aims to lower drug prices but faces constitutional challenges from pharmaceutical companies over pricing and First and Fifth Amendment rights.

Drug pricing reform was excluded from a spending bill, disappointing advocates seeking meaningful changes before year-end.

New bipartisan legislation seeks to prevent health insurers from owning pharmacies, targeting the monopolistic power of pharmacy benefit managers.

If enacted, this legislation could disrupt the current healthcare market dominated by a few conglomerates. The effort highlights ongoing concerns about drug pricing and transparency.

FTC report reveals significant price hikes by PBMs on critical medications, calling for investigations into practices inflating drug costs and harming healthcare accessibility.

The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.

Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.

Wegovy's price in China is substantially lower than in the US, highlighting global disparities in drug pricing.

High prices for diabetes and obesity drugs like Ozempic are jeopardizing patient access, especially among low-income and minority groups.

Candidates Harris and Trump plan to tackle U.S. health care issues but propose vastly different policies affecting drug costs and access to care.

Ozempic is likely to be included in upcoming drug price negotiations with the US government.

Ozempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.